Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with type-2 diabetes and patients with obesity.
As part of the agreement, Boehringer Ingelheim obtains global development and commercialisation rights to ZP2929, Zealand Pharma’s lead glucagon/GLP-1 dual agonist drug candidate. Zealand Pharma will be responsible for conducting the first Phase I study with ZP2929 and Boehringer Ingelheim will fund the research, development and commercialisation of products under the agreement.
Depending on the achievement of pre-defined development, regulatory and commercial milestones, Zealand Pharma is eligible to receive payments for ZP2929 and may also receive additional milestone payments if other products covered by the collaboration are advanced through development. Further, Zealand Pharma is entitled to tiered royalties that range from high single to low double digits on global sales of products under the agreement. Zealand Pharma retains co-promotion rights in Scandinavia.
During the first two years of collaboration, Zealand Pharma is eligible to receive signature, milestone, and other payments of up to €41 million including cost reimbursements and including research funding of up to €4 million. In their research collaboration, Zealand Pharma and Boehringer Ingelheim will focus on the characterization, identification and development of additional glucagon/GLP-1 dual agonists for the exploration of new indications, formulations and delivery systems.
David H Solomon, president and chief executive officer of Zealand Pharma, said: “We are extremely pleased to have signed this license and collaboration agreement with Boehringer Ingelheim, which has recently strengthened its commitment to the important field of diabetes. ZP2929 is one of Zealand Pharma's most innovative peptide drug candidates, having shown significant pre-clinical promise for patients with type 2 diabetes and obesity. Together with Boehringer Ingelheim, we look forward to advancing the development of ZP2929 into phase I as part of our joint efforts to bring novel and better treatments to the market to help improve the lives of diabetes patients.”
Boehringer Ingelheim's corporate senior vice president Medicine, Prof Dr Klaus Dugi commented: “Our focus to develop innovative diabetes treatments is reinforced by the in-licensing of a very interesting compound from Zealand Pharma which complements Boehringer Ingelheim’s pipeline in diabetes and metabolic diseases very well. With our first diabetes treatment linagliptin recently approved by the FDA, we have a manifest for Boehringer Ingelheim’s own research strength and its capability to bring novel medication to the patients. We are therefore pleased to bundle our R&D experience with Zealand Pharma for further projects in diabetes and obesity.”
The biological rationale for developing ZP2929 is based on the pharmacology of the gut peptide hormone oxyntomodulin. Oxyntomodulin is released by the L-cells of the small intestine after meals, and is believed to exert its biological effects by activating both the glucagon receptor and the GLP-1 receptor. In humans, this hormone is believed to have multiple beneficial effects on diabetes and obesity, improving glucose tolerance and causing substantial weight loss.
ZP2929, which acts on both the glucagon and GLP-1 receptors, has shown in preclinical studies the ability to achieve glycaemic control while causing significant and sustained weight loss. ZP2929 is being developed for once-daily subcutaneous administration to improve glycaemic control and induce weight loss in patients with type 2 diabetes and patients with obesity.
ZP2929 is not part of Boehringer Ingelheim’s strategic diabetes alliance with Eli Lilly and Company.
Zealand Pharma A/S is a public biopharmaceutical company with a mature and growing clinical pipeline of innovative peptide based drugs.It specializes in the discovery, optimization and development of novel peptide drugs with favourable therapeutic attributes, and all drug candidates in its pipeline have been identified through the company’s own drug discovery activities.
The Boehringer Ingelheim group is committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.